杂种旨在改变科学软件和数据管理的未来
杂种旨在改变科学软件和数据管理的未来
Scientific R&D and innovation is undergoing a pivotal transformation. Scientific knowledge and growth in pharmaceutical drug discovery and chemicals & materials innovation is increasing at a faster pace than ever before.
COVID highlighted the need for rapid acceleration of scientific research and collaboration to lead to faster, more successful breakthroughs. Yet the complexity of getting and using scientific data in meaningful ways has led to compromised success and delayed results among researchers and scientists. The industry has been missing an integrated R&D platform with the depth, breadth, and connectivity to other applications to solve the complex data challenges in labs.
Dotmatics Combines an Integrated R&D Platform with Applications to Solve Workflow and Data Complexities
Dotmatics offers capabilities to exponentially transform R&D productivity with a platform that connects and organizes data that is distributed across organizations or industries and combines it with market-leading science applications for quick access, collaboration, and informed decision-making.
“Companies that own the cleanest, best annotated data to power their AI analytics and decision making will be the best positioned to succeed in this new paradigm,” said Thomas Swalla, CEO of Dotmatics. “We are going to market under the consolidated brand Dotmatics reflecting the enormous power of the Company to provide this capability to our customers. We can transform scientific R&D with a platform that addresses the data challenges and then connects industry-favorite applications to better harmonize science and data.”
One such company aiming to harmonize their science and data is Debiopharm. Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, they identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.
"Dotmatics has truly disrupted the way Debiopharm works for the better. All our data is now available and accessible at all times,” said René van den Bersselaar Global Head IT and CIO at Debiopharm. “But more than that, Dotmatics has helped change the mindset in the company; we’re now making better, more data-driven decisions, helping us be more competitive and allowing us to get new therapies to patients faster.”
More than two million scientists and 10,000 customers from the world’s leading biotech, biopharma, chemicals & materials organizations, and academic institutions trust Dotmatics to help accelerate innovation and help make the world a healthier, cleaner, safer place to live.
“Our combined team of 800+ employees at Dotmatics are working together to eliminate the workarounds and decision-making challenges scientists are facing in today’s market,” said Mike McKee, President of Dotmatics. “Today we are helping to solve these challenges for companies like BAS-F, Merck, and Novartis Pharma AG and research universities like MIT and Oxford, providing them with solutions that harmonize science and data to create a better future together.”
Following the merger of Insightful Science and Dotmatics in March 2021, a global team of 800+ employees support its customers in more than 180 countries. Dotmatics has recently added strategic executive hires including a CFO, CRO, and CMO and will continue to build and acquire leading scientific software applications that are critical in lab research. The combined company has been and continues to be profitable and will scale to more than $200M ARR this year. It will continue to execute on its inorganic growth strategy by building on 2021 momentum where Dotmatics deployed approximately $1 billion dollars of capital to acquire five leading scientific software applications that are critical in lab research.
">
填写下面的表格，我们将向您发送PDF版本的电子邮件"Dotmatics Set To Transform the Future of Scientific Software and Data Management"
Dotmatics已被宣布为有见识的科学和杂种学实体的正式名称和品牌。随着有见地的科学品牌退休，新的杂种公司现在已包含Dotmatics’ enterprise scientific platform以及许多科学家最喜欢的应用程序SnapGene，，，，祖， 和GraphPad Prism提供生物学，化学和配方研究与开发的端到端解决方案。
Scientific R&D and innovation is undergoing a pivotal transformation. Scientific knowledge and growth in pharmaceutical drug discovery and chemicals & materials innovation is increasing at a faster pace than ever before.
COVID highlighted the need for rapid acceleration of scientific research and collaboration to lead to faster, more successful breakthroughs. Yet the complexity of getting and using scientific data in meaningful ways has led to compromised success and delayed results among researchers and scientists. The industry has been missing an integrated R&D platform with the depth, breadth, and connectivity to other applications to solve the complex data challenges in labs.
Dotmatics将集成的研发平台与解决工作流程和数据复杂性的应用程序结合在一起
Dotmatics提供了通过一个平台来指数级转换研发生产力的功能，该平台连接和组织了在组织或行业之间分发的数据，并将其与市场领先的科学应用程序相结合，以快速访问，协作和知情的决策。
“Companies that own the cleanest, best annotated data to power their AI analytics and decision making will be the best positioned to succeed in this new paradigm,”Dotmatics首席执行官Thomas Swalla说。“We are going to market under the consolidated brand Dotmatics reflecting the enormous power of the Company to provide this capability to our customers. We can transform scientific R&D with a platform that addresses the data challenges and then connects industry-favorite applications to better harmonize science and data.”
One such company aiming to harmonize their science and data is Debiopharm. Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, they identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.
“ Dotmatics确实破坏了Debiopharm的工作方式。said René van den Bersselaar Global Head IT and CIO at Debiopharm.“但不仅如此，Dotmatics帮助改变了公司的思维方式；现在，我们正在做出更好，更多的数据驱动决定，帮助我们更具竞争力，并使我们能够更快地为患者获得新的疗法。”
来自世界领先的生物技术，生物制药，化学和材料组织和学术机构的超过200万科学家和10,000名客户信任多样化的人，以帮助加速创新并帮助世界成为更健康，更清洁，更安全的生活场所。
“我们在Dotmatics的800多名员工组成的团队正在共同努力，以消除科学家在当今市场上面临的解决方法和决策挑战，”said Mike McKee, President of Dotmatics.“Today we are helping to solve these challenges for companies like BAS-F, Merck, and Novartis Pharma AG and research universities like MIT and Oxford, providing them with solutions that harmonize science and data to create a better future together.”
在2021年3月合并了有见地的科学和杂乱无章之后，由800多名员工组成的全球团队在180多个国家 /地区为客户提供支持。Dotmatics最近增加了战略执行员工首席财务官，，，，CRO, and CMO并将继续构建和获取在实验室研究中至关重要的领先的科学软件应用程序。合并后的公司已经并且继续保持盈利，今年将扩大到超过2亿美元的ARR。它将通过在2021年的势头上建立动力来继续执行其无机增长策略，在该动力上，Dotmatics部署了约10亿美元的资本，以获取五个在实验室研究中至关重要的领先的科学软件应用程序。
